CO2022010294A2 - Anticuerpos cd163 o proteinas de union - Google Patents

Anticuerpos cd163 o proteinas de union

Info

Publication number
CO2022010294A2
CO2022010294A2 CONC2022/0010294A CO2022010294A CO2022010294A2 CO 2022010294 A2 CO2022010294 A2 CO 2022010294A2 CO 2022010294 A CO2022010294 A CO 2022010294A CO 2022010294 A2 CO2022010294 A2 CO 2022010294A2
Authority
CO
Colombia
Prior art keywords
porcine
antigen
binds
amino acid
binding domain
Prior art date
Application number
CONC2022/0010294A
Other languages
English (en)
Spanish (es)
Inventor
Charles Owen
Hafid Abdelaali Benchaoui
Christine Tait-Burkard
Original Assignee
Eco Animal Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eco Animal Health Ltd filed Critical Eco Animal Health Ltd
Publication of CO2022010294A2 publication Critical patent/CO2022010294A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CONC2022/0010294A 2019-12-24 2022-07-21 Anticuerpos cd163 o proteinas de union CO2022010294A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1919294.7A GB201919294D0 (en) 2019-12-24 2019-12-24 Antibodies or binding proteins
PCT/GB2020/053370 WO2021130502A1 (en) 2019-12-24 2020-12-24 Cd163 antibodies or binding proteins

Publications (1)

Publication Number Publication Date
CO2022010294A2 true CO2022010294A2 (es) 2022-10-31

Family

ID=69322779

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0010294A CO2022010294A2 (es) 2019-12-24 2022-07-21 Anticuerpos cd163 o proteinas de union

Country Status (13)

Country Link
US (1) US20230203185A1 (https=)
EP (1) EP4081542A1 (https=)
JP (1) JP7702952B2 (https=)
KR (1) KR20220119147A (https=)
CN (1) CN121873247A (https=)
BR (1) BR112022012362A2 (https=)
CL (1) CL2022001706A1 (https=)
CO (1) CO2022010294A2 (https=)
DO (2) DOP2022000136A (https=)
GB (1) GB201919294D0 (https=)
MX (1) MX2022007957A (https=)
PE (1) PE20230384A1 (https=)
WO (1) WO2021130502A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR129879A1 (es) * 2022-07-08 2024-10-09 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
GB202214979D0 (en) * 2022-10-11 2022-11-23 Eco Animal Health Ltd Binding protein
WO2024156888A1 (en) * 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119569865B (zh) * 2024-12-20 2025-10-10 西北农林科技大学 一种防治猪繁殖与呼吸障碍综合征病毒感染的混合制剂及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3331355T3 (fi) * 2015-08-06 2024-06-17 Univ Missouri Sikojen lisääntymishäiriö- ja keuhkotulehdusoireyhtymävirukselle (PRRSV) resistentti sika ja soluja, joilla on muokattuja CD163-geenejä
US11160260B2 (en) * 2018-04-17 2021-11-02 The Curators Of The University Of Missouri Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV)

Also Published As

Publication number Publication date
US20230203185A1 (en) 2023-06-29
JP2023508674A (ja) 2023-03-03
CA3162664A1 (en) 2021-07-01
JP7702952B2 (ja) 2025-07-04
PE20230384A1 (es) 2023-03-06
EP4081542A1 (en) 2022-11-02
DOP2022000136A (es) 2022-11-30
DOP2025000290A (es) 2026-02-26
CL2022001706A1 (es) 2023-05-26
KR20220119147A (ko) 2022-08-26
BR112022012362A2 (pt) 2022-09-06
GB201919294D0 (en) 2020-02-05
MX2022007957A (es) 2022-10-07
WO2021130502A1 (en) 2021-07-01
CN121873247A (zh) 2026-04-17
CN115151569A (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
CO2022010294A2 (es) Anticuerpos cd163 o proteinas de union
CL2021000739A1 (es) Moléculas de unión a antígeno capaces de unirse al cúmulo de diferenciación 3 (cd3) y al cúmulo de diferenciación 137 (cd137) pero no simultáneamente
CR20200579A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
AR109882A1 (es) Anticuerpos monoclonales neutralizantes anti-tl1a
IL299221A (en) Cd3 binding antibodies
HRP20241381T1 (hr) Nova anti-pd-1 protutijela
UY37694A (es) Dominios de unión a antígeno humanizados y métodos de uso
BR112019003775A2 (pt) anticorpo monoclonal anti-pd1, composição farmacêutica do mesmo e uso dos mesmos
PE20120475A1 (es) Anticuerpos especificos para dkk-1
CO2023009615A2 (es) Anticuerpos multiespecíficos que tienen especificidad para il-4r e il-31
PE20141433A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20230839A1 (es) Agentes de union a lair-1 y metodos para su uso
PE20230306A1 (es) Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso
DOP2018000234A (es) Anticuerpos anti-basigin humanizados y uso de los mismos
CO2021014153A2 (es) Anticuerpo monoclonal que se une específicamente a gitr
EA201792329A1 (ru) Способ мономеризации рекомбинантных молекул антител
IL250289B2 (en) Antibodies against angiopoietin-like 4 and methods of use
WO2020257789A3 (en) Anti-tim-3 antibodies
AR087485A1 (es) Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
BR112022011323A2 (pt) Anticorpo biespecífico anti-antígeno de maturação de célula b (bcma)/anti-4-1bb ou um fragmento de ligação ao antígeno do mesmo, e composição farmacêutica para prevenção ou tratamento de uma doença relacionada ao bcma, 4-1bb ou ambos
EA201991510A1 (ru) Каркасы антител для снижения агрегирования полиспецифических антител
BR112022006364A2 (pt) Anticorpo híbrido
JPWO2020028428A5 (https=)
AR126971A1 (es) Composiciones y métodos para tratar el síndrome de qt largo